Sino Biopharmaceutical repurchases €157.77 million 0% convertibles

By Rebecca Melvin

Concord, N.H., May 20 – Sino Biopharmaceutical Ltd. repurchased €157,768,000 of its 0% convertible bonds due 2025 as of May 20, according to a company notice.

The purchase represents 21% of the €750 million originally issued.

The repurchased bonds will be canceled as soon as practicable.

Following the cancellation, there will be €592,232,000 principal amount outstanding.

Sino Biopharmaceutical is a Hong Kong-based medicine products business.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.